![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
L Lacinova, A Welling, E Bosse, P Ruth, V Flockerzi and F Hofmann
Institut fur Pharmakologie und Toxikologie, Technischen Universitat, Munchen, Germany.
The interaction of the nondihydropyridine calcium channel antagonist Ro 40-5967 with the stably expressed class C alpha 1-subunit of the cardiac L-type calcium channel was investigated and compared with that of verapamil by using the whole cell patch clamp configuration. Both compounds blocked the Ba++ inward current. The IC50 values at a holding potential of -80 or -40 mV were 4.9 and 1.4 microM for Ro 40-5967 and 250 and 15.5 microM for verapamil. Both Ro 40-5967 and verapamil induced a partial tonic block at a holding potential of -80 mV. The block increased with high depolarization rates. Both Ro 40-5967 and verapamil shifted the steady-state inactivation curve by more than 20 mV to hyperpolarized membrane potentials and decreased the inactivation rate constant. The effect of Ro 40-5967, but not that of verapamil, was attenuated by intracellular dialysis with GTP gamma S. The affinity for verapamil was not affected by replacing Ba++ by Ca++, but was increased by the coexpression of the beta 3-subunit. These results indicate that both compounds interact with high affinity with the inactivated channel state, but may interact additionally with the open channel.
This article has been cited by other articles:
|
|
 |
|
  M. Subramanian and C. Shaha Up-Regulation of Bcl-2 through ERK Phosphorylation Is Associated with Human Macrophage Survival in an Estrogen Microenvironment J. Immunol., August 15, 2007; 179(4): 2330 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murakami, H. Yamamura, T. Suzuki, M.-G. Kang, S. Ohya, A. Murakami, I. Miyoshi, H. Sasano, K. Muraki, T. Hano, et al. Modified Cardiovascular L-type Channels in Mice Lacking the Voltage-dependent Ca2+ Channel {beta}3 Subunit J. Biol. Chem., October 31, 2003; 278(44): 43261 - 43267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Martin, J.-H. Lee, L. L. Cribbs, E. Perez-Reyes, and D. A. Hanck Mibefradil Block of Cloned T-Type Calcium Channels J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 302 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
M. F. Rossier, E. A. Ertel, M. B. Vallotton, and A. M. Capponi Inhibitory Action of Mibefradil on Calcium Signaling and Aldosterone Synthesis in Bovine Adrenal Glomerulosa Cells J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 824 - 831. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. H. Frishman Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 321 - 330. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
